 Connection
Joseph Saseen to Cholesterol, LDL
This is a "connection" page, showing publications Joseph Saseen has written about Cholesterol, LDL.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.841 |
|
|
|
-
Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 2021 08; 35(4):853-864.
Score: 0.655
-
Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy. 2008 May; 28(5):553-61.
Score: 0.267
-
Marrs JC, Saseen JJ. Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients. Pharmacotherapy. 2008 May; 28(5):562-9.
Score: 0.267
-
Dixon DL, Saseen JJ. Pharmacist-administered long-acting injectable PCSK9 service: A solution to improve patient access and adherence. J Am Pharm Assoc (2003). 2021 May-Jun; 61(3):e83-e85.
Score: 0.161
-
Moore GD, Kosirog ER, Vande Griend JP, Freund JE, Saseen JJ. Expansion of clinical pharmacist positions through sustainable funding. Am J Health Syst Pharm. 2018 Jul 01; 75(13):978-981.
Score: 0.135
-
Zupec JF, Marrs JC, Saseen JJ. Evaluation of Statin Prescribing for Secondary Prevention in Primary Care Following New Guideline Recommendations. Ann Pharmacother. 2016 Jan; 50(1):17-21.
Score: 0.112
-
Marrs JC, Saseen JJ. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis. Pharmacotherapy. 2010 Aug; 30(8):823-9.
Score: 0.078
-
Nair KV, Saseen JJ. Quality assessment of dyslipidemia in managed care: current best evidence should be used to benchmark quality. Ann Pharmacother. 2006 Jan; 40(1):124-7.
Score: 0.057
-
Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D, Orringer CE, Saseen JJ, Smith SC, Sperling LS, Virani SS. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
Score: 0.042
-
Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, Goldberg A, Jones LK, Maki K, Dixon DL, Saseen JJ, Soffer D. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. J Clin Lipidol. 2019 Jul - Aug; 13(4):525-537.
Score: 0.036
-
Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. J Clin Lipidol. 2017 Jan - Feb; 11(1):70-79.e1.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|